Physician profile
Madison Bloom
NPI 1003680919
$7,400.55
in general payments reported to CMS, 2019-2025
22 companies · $5,881 in 2025
The $5,881 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,520 · 2025: $5,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,172 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,171.57 |
| Education | $228.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,125.16 | 2024-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $978.20 | 2024-2025 | Krystexxa, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $831.10 | 2024-2025 | |
| Abbvie INC. | $786.46 | 2024-2025 | |
| Ucb, INC. | $767.86 | 2024-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $507.31 | 2024-2025 | Saphnelo |
| Organon LLC | $225.92 | 2024-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $177.14 | 2025 | |
| Pfizer INC. | $156.18 | 2025 | |
| Ani Pharmaceuticals, INC. | $150.81 | 2024-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $135.43 | 2025 | Taltz, Zepbound |
| Fresenius Kabi USA, LLC | $123.01 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $104.98 | 2025 | Orencia |
| Sandoz INC. | $56.82 | 2025 | Hyrimoz, Jubbonti |
| Janssen Scientific Affairs, LLC | $45.74 | 2025 | Tremfya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $43.98 | 2025 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $40.83 | 2025 | Opsumit |
| Genentech USA, INC. | $38.71 | 2025 | Gazyva, Actemra |
| Alvogen INC | $38.52 | 2024-2025 | Teriparatide |
| Sobi, INC | $23.93 | 2024 | |
| Genzyme Corporation | $22.44 | 2025 | |
| Kyowa Kirin, INC. | $20.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.